SC
LSTA icon

Sophrosyne Capital’s Lisata Therapeutics LSTA Stock Holding History

Sophrosyne Capital’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-941
Closed -$963K – 85
2013
Q4 		$963K Buy
941
+467
+99% +$462K 0.84% 30
2013
Q3 		$607K Buy
+474
New +$526K 0.4% 47

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sophrosyne Capital's LSTA Position: Q1 2014 in Review

Sophrosyne Capital sold out of Lisata Therapeutics (LSTA) in Q1 2014, closing a stake of 941 shares — an estimated $963K sold.

Sophrosyne Capital first reported a position in LSTA in Q3 2013 and held it in 2 quarters. The position peaked at $963K in Q4 2013. 38 funds tracked by Wall St. Rank hold LSTA as of Q1 2014.

  • Sophrosyne Capital reported no remaining Lisata Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 941 Lisata Therapeutics shares in Q1 2014, an estimated $963K.
  • Sophrosyne Capital first reported a position in Lisata Therapeutics in Q3 2013 and held it in 2 quarters.
  • Sophrosyne Capital's Lisata Therapeutics position peaked at $963K in Q4 2013.
  • 38 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2014.

Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.